Are Aquous Based Immunotherapy Vaccines Safe and Effective?


Committed to Patient Safety

Aqueous-based vaccines are proven to be a safe form of treatment.

The American Academy of Allergy, Asthma and Immunology and The American College of Allergy, Asthma, and Immunology members complete an annual survey of related Systemic Reactions (SR’s) of varying severity.  Over an 8-year period,  covering a total of 54.4million injections overall reported systemic reactions averaged only 8.7 per 10,000 injections, including:

  • 5.6 per 10,000 injections of these were grade 1 SR’s (mild)
  • 2.7 per 10,000 injections were grade 2 SR’s (moderate)
  • 0.35 per 10,000 injections were grade 3 SR’s (severe)
  • 1 per 160,000 were grade 4 (very severe)

Furthermore 75% of systemic reactions were observed within 30min of the injection being given, reinforcing the protocol of patient observation followin immunotherapy treatment.


Gold Standard in Allergy Treatment

Gamma Allergy’s Alleraq and Alleraq+ are a subcutaneous class of immunotherapy and considered the gold standard of treatment throughout North America. Delivered via injection, aqueous-based Immunotherapy is an established, safe and effective allergy treatment, backed by decades of peer reviewed studies.

Our Alleraq and Alleraq+ vaccines are the most widely prescribed allergy vaccines throughout North America. For over 30 years their efficacy has been demonstrated through numerous  double-blind, placebo controlled, randomized clinical trials.

They are frequently used in the effective treatment of allergic rhinitis, allergic asthma and inhalant allergies caused by pollens, fungi, animal allergens, dust mites or roaches.


Leaders in Quality and Range

With over 200 individual and standard mixes available for compounding, our diagnostic antigens make up some of the largest Skin Prick Testing range available in Australia.

Like our immunotherapy sets, our antigens are manufactured in North America in accordance with stringent regulations as set by the FDA and Health Canada, making them world-leaders and recognised as significantly higher quality than available alternatives.



AAAAI/ACAAI Subcutaneous Immunotherapy Surveillance Study (2013-2017): Fatalities, Infections, Delayed Reactions, and Use of Epinephrine Autoinjectors

Tolly G. Epstein, MD, MSa,b, Gary M. Liss, MD, MSc, Karen Murphy Berendts, BSd, and David I. Bernstein, MDa,d
Cincinnati, Ohio; Indianapolis, Ind; and Toronto, Ontario, Canada

Link to Study